Glomerulosclerosis Clinical Trials

28 recruitingLast updated: May 13, 2026

There are 28 actively recruiting glomerulosclerosis clinical trials across 47 countries. Studies span Phase 2, Not Applicable, Phase 1, Phase 3, Phase 4. Top locations include New York, New York, United States, Philadelphia, Pennsylvania, United States, Ann Arbor, Michigan, United States. Updated daily from ClinicalTrials.gov.


Glomerulosclerosis Trials at a Glance

28 actively recruiting trials for glomerulosclerosis are listed on ClinicalTrialsFinder across 6 cities in 47 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in New York, Philadelphia, and Ann Arbor. Lead sponsors running glomerulosclerosis studies include University of Michigan, Northwell Health, and Kaneka Medical America LLC.

Browse glomerulosclerosis trials by phase

Treatments under study

About Glomerulosclerosis Clinical Trials

Looking for clinical trials for Glomerulosclerosis? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Glomerulosclerosis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Glomerulosclerosis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 28 trials

Recruiting
Phase 2

An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis

Focal Segmental Glomerulosclerosis
National Human Genome Research Institute (NHGRI)30 enrolled1 locationNCT06664814
Recruiting
Phase 2

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Alport SyndromeFocal Segmental GlomerulosclerosisImmunoglobulin A Nephropathy+2 more
Travere Therapeutics, Inc.67 enrolled47 locationsNCT05003986
Recruiting
Not Applicable

NEPTUNE Match Study

Nephrotic Syndrome in ChildrenAlport SyndromeFocal Segmental Glomerulosclerosis+6 more
University of Michigan375 enrolled16 locationsNCT04571658
Recruiting
Phase 2

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease

Focal Segmental GlomerulosclerosisGlomerulonephritis Minimal Lesion
Sanofi84 enrolled69 locationsNCT06500702
Recruiting
Phase 3

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis
Boehringer Ingelheim286 enrolled256 locationsNCT07220083
Recruiting

Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease

Focal Segmental GlomerulosclerosisMinimal Change DiseaseFSGS+1 more
University of Michigan300 enrolled1 locationNCT05650619
Recruiting
Phase 2

A Study of Praliciguat in Participants With Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis
Akebia Therapeutics60 enrolled10 locationsNCT07268638
Recruiting
Not Applicable

A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS)

Nephrotic Syndrome in ChildrenFocal Segmental GlomerulosclerosisMinimal Change Disease
Northwell Health10 enrolled2 locationsNCT05583942
Recruiting
Not Applicable

taVNS for FRNS in Children

Nephrotic Syndrome in ChildrenFocal Segmental GlomerulosclerosisMinimal Change Disease
Northwell Health30 enrolled2 locationsNCT05588063
Recruiting
Not Applicable

SLIT ABS: Study on Patients With Autoimmune Podocytopathy

Focal segmental glomerulosclerosis (FSGS)Nephrotic Syndrome Due to Idiopathic Membranous NephropathyMinimal Change Nephrotic Syndrome+1 more
Meyer Children's Hospital IRCCS50 enrolled14 locationsNCT07516964
Recruiting
Phase 2Phase 3

A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS)Minimal Change Disease (MCD)
Bio-Thera Solutions192 enrolled1 locationNCT07499700
Recruiting
Phase 2

Study of WAL0921 in Patients With Glomerular Kidney Diseases

Diabetic NephropathiesPrimary Focal Segmental GlomerulosclerosisMinimal Change Disease+2 more
Walden Biosciences96 enrolled50 locationsNCT06466135
Recruiting

INS, B Cells and Microbiota

MicrobiotaB-lymphocytesGlomerulosclerosis+1 more
Nantes University Hospital30 enrolled2 locationsNCT04924712
Recruiting

Transformative Research in Diabetic Nephropathy

Diabetic NephropathiesDiabetic Glomerulosclerosis
University of Pennsylvania400 enrolled17 locationsNCT02986984
Recruiting
Phase 4

Sparsentan in Posttransplant Immunoglobulin A Nephropathy or Focal Segmental Glomerulosclerosis

Kidney TransplantFocal Segmental GlomerulosclerosisProteinuria+1 more
Travere Therapeutics, Inc.20 enrolled9 locationsNCT07219121
Recruiting
Phase 1Phase 2

AMPK-activation by Metformin in FSGS: AMP-FSGS

Focal Segmental Glomerulosclerosis
Yale University30 enrolled2 locationsNCT06090227
Recruiting

Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.

EdemaNephrotic Syndrome in ChildrenMembranous Nephropathy+10 more
University of Michigan150 enrolled1 locationNCT05505500
Recruiting

The FOrMe Registry (The German Focal Segmental Glomerulosclerosis and Minimal Change Disease Registry)

Minimal Change DiseaseGlomerulosclerosis, Focal SegmentalIdiopathic Nephrotic Syndrome
Prof. Dr. Paul Brinkkoetter500 enrolled12 locationsNCT03949972
Recruiting
Phase 1

A Phase 1 Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of VIS171 in Participants With Autoimmune Disease(s)

Systemic Lupus Erythematosus (SLE)Alopecia Areata (AA)Immune-mediated Focal Segmental Glomerulosclerosis (FSGS)
Otsuka Pharmaceutical Development & Commercialization, Inc.30 enrolled6 locationsNCT06799520
Recruiting
Not Applicable

Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children

Focal Segmental Glomerulosclerosis
Kaneka Medical America LLC35 enrolled12 locationsNCT02235857